Immunome Inc (IMNM) - Total Liabilities
Based on the latest financial reports, Immunome Inc (IMNM) has total liabilities worth $48.84 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Immunome Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Immunome Inc's total liabilities have evolved over time, based on quarterly financial data. See Immunome Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Immunome Inc Competitors by Total Liabilities
The table below lists competitors of Immunome Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Navitas Semiconductor Corp
NASDAQ:NVTS
|
USA | $59.22 Million |
|
Íslandsbanki hf.
IC:ISB
|
Iceland | Ikr1.47 Trillion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $101.22 Million |
|
Glodon Software Co Ltd
SHE:002410
|
China | CN¥3.33 Billion |
|
Dlocal Ltd
NASDAQ:DLO
|
USA | $971.53 Million |
|
Inari Amertron Bhd
KLSE:0166
|
Malaysia | RM308.02 Million |
|
Odfjell Drilling Ltd
OL:ODL
|
Norway | Nkr1.25 Billion |
|
Dynapack International Technology
TWO:3211
|
Taiwan | NT$5.62 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Immunome Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Immunome Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunome Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunome Inc (2018–2025)
The table below shows the annual total liabilities of Immunome Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $48.84 Million | -17.32% |
| 2024-12-31 | $59.08 Million | +106.14% |
| 2023-12-31 | $28.66 Million | +287.64% |
| 2022-12-31 | $7.39 Million | -24.10% |
| 2021-12-31 | $9.74 Million | +206.29% |
| 2020-12-31 | $3.18 Million | -92.18% |
| 2019-12-31 | $40.69 Million | +37.22% |
| 2018-12-31 | $29.65 Million | -- |
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine… Read more